127 related articles for article (PubMed ID: 16808310)
1. [Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis].
Dyjas R; Bułanowski M; Ficek R; Witkowicz J; Chudek J; Wiecek A
Pol Arch Med Wewn; 2005 Aug; 114(2):731-7. PubMed ID: 16808310
[TBL] [Abstract][Full Text] [Related]
2. Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients.
Kokot F; Wiecek A; Schmidt-Gayk H; Marcinkowski W; Nieszporek T; Rudka R; Trembecki J
Przegl Lek; 1992; 49(1-2):43-9. PubMed ID: 1455006
[TBL] [Abstract][Full Text] [Related]
3. [Does long-term human recombinant erythropoietin (rHuEPO) influence secretion of hormones regulating volume and pressure of arterial blood?].
Rudka R; Kokot F; Wiecek A; Marcinkowski W; Trembecki J
Pol Arch Med Wewn; 1994 Aug; 92(2):154-61. PubMed ID: 7800584
[TBL] [Abstract][Full Text] [Related]
4. Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic peptide in haemodialyzed patients.
Kokot F; Wiecek A; Grzeszczak W; Klin M
Miner Electrolyte Metab; 1990; 16(1):25-9. PubMed ID: 2139159
[TBL] [Abstract][Full Text] [Related]
5. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
[TBL] [Abstract][Full Text] [Related]
6. The effects of recombinant human erythropoietin on autologous blood donation in rheumatoid arthritis patients with anaemia.
Matsui H; Shiraishi N; Yasuda T; Nezuka T
Clin Exp Rheumatol; 1999; 17(1):69-74. PubMed ID: 10084035
[TBL] [Abstract][Full Text] [Related]
7. Autologous blood transfusion with recombinant erythropoietin treatment in anaemic patients with rheumatoid arthritis.
Tanaka N; Ito K; Ishii S; Yamazaki I
Clin Rheumatol; 1999; 18(4):293-8. PubMed ID: 10468168
[TBL] [Abstract][Full Text] [Related]
8. [Influence of parathormone level on the doses of human recombinant erythropoietin in haemodialysed patients].
Zelichowski G; Olszowska A; Lubas A; Wańkowicz Z
Pol Merkur Lekarski; 2002 Nov; 13(77):373-5. PubMed ID: 12621751
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease.
Salvarani C; Lasagni D; Casali B; Macchioni P; Boiardi L; Rossi F; Rivasi P; Portioli I
J Rheumatol; 1991 Aug; 18(8):1168-71. PubMed ID: 1941817
[TBL] [Abstract][Full Text] [Related]
10. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability.
Linde T; Sandhagen B; Wikström B; Danielson BG
Nephrol Dial Transplant; 1997 Nov; 12(11):2375-9. PubMed ID: 9394325
[TBL] [Abstract][Full Text] [Related]
11. The use of recombinant human erythropoietin (rHuEpo) in humans.
Adamson JW; Eschbach JW
Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
[TBL] [Abstract][Full Text] [Related]
12. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension.
Sasagawa I; Nakada T; Hashimoto T; Kubota Y; Suzuki H; Sawamura T
Int Urol Nephrol; 1994; 26(2):237-43. PubMed ID: 8034437
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
[TBL] [Abstract][Full Text] [Related]
14. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
[TBL] [Abstract][Full Text] [Related]
15. Influence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients.
Hsu SP; Peng YS; Pai MF; Hung KY; Tsai TJ
Blood Purif; 2003; 21(3):220-4. PubMed ID: 12784047
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin and the anemia of chronic diseases.
De Marchi S; Pirisi M; Ferraccioli GF
Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
[TBL] [Abstract][Full Text] [Related]
17. [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure].
Trembecki J; Kokot F; Wiecek A; Marcinkowski W; Rudka R
Pol Arch Med Wewn; 1995 Aug; 94(2):144-52. PubMed ID: 8596749
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
